Webinars and Sponsored Roundtables — Register Now

Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center

CAP TODAY does not endorse any of the products or services named within. The roundtable is made possible by a special educational grant from Pillar Biosciences.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.

Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Illumina.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.

Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Tuesday, November 3, 2026 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.

Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Subspecialties

Interactive Product Guides

Product Spotlight

HORIBA

Yumizen C560

Company

HORIBA

Name of instrument

Yumizen C560

Contact

Brooke Bradley   

Email

medical-marketing.us@horiba.com

City, State

Canton, MI

Phone

734-487-8300   

Website

http://www.horiba.com

Type of instrument

chemistry

List price/First year sold in U.S.

$110,000/2023

Targeted hospital bed size/Targeted test volume

< 275/daily: 3,000; monthly: 60,000; annual: 720,000

Company manufactures instrument

yes (also sold by distribution partners)

Other models in this family of analyzers

Yumizen C230, Yumizen C240

No. of units in clinical use in U.S./Outside U.S. (countries)

—

Dimensions (H × W × D)/Instrument footprint

45 × 46 × 28 in./35 sq. ft.

Weight empty/Weight fully loaded

661 lbs./—

No. of different measured assays onboard simultaneously

81 (up to 81 can be run and calibrated at one time)

No. of user-definable (open chemistry) channels

up to 50 (50 can be active simultaneously)

Test throughput per hour/Assay run time

560/1–10 min. (avg. 8 min.)

No. of direct ion-selective electrode channels

3

Detection methods

photometry, potentiometry

Stat time until completion/specimen throughput for Ion-selective electrode

~4.2 min./~56 specimens per hr.

Stat time until completion/specimen throughput for Ion-selective electrode basic metabolic panel

~7.7 min./~53 specimens per hr.

Stat time until completion/specimen throughput for Ion-selective electrode complete metabolic panel

~10.5 min./~50 specimens per hr.

Typical time delay from ordering stat test until aspiration of sample

~135 sec. 

Fully automated microplate immunoassay system

—

Methodologies supported

—

Separation methodologies

—

Stat time until completion of a ß-hCG test

—

Stat time until completion of a cTn test

—

• Typical time delay from test order to aspiration of sample

—

Reagents refrigerated onboard/Reagents ready to use

yes (2°–10°C)/variable; reagent specific

Reagent lot tracking/Reagent inventory

yes/yes

Reagent form/Reagents barcoded

liquid chemistry (open reagent system)/yes

Separate reagent pack for each specimen/for each test run

no/no

Walkaway capability/Walkaway duration

yes/143 min. or 87 specimens or 14 test panels

Design of sample-handling system

ring

Uses washable cuvettes/Uses disposable cuvettes

yes/no (can store up to 90 cuvettes)

Min.–max. sample volume that can be aspirated at one time 

1.5–45 µL

Min. reaction volume/Min. specimen volume/Min. dead volume

120 µL/75 µL (test dependent)/70 µL

Dedicated pediatric sample cup

yes (dead volume: 70 µL)

Primary tube sampling

yes

Accommodates most standard tube sizes/Accepts nonstandard tube sizes

yes/—

Pierces caps on primary tubes

no

Protects against probe collision

yes

Detects clots/liquid level/short sample

yes/yes/yes

Detection or quantitation for hemolysis, icterus, lipemia, clots

detection and quantitation for hemolysis, icterus, lipemia; detection for clots

Dilutes patient samples onboard/Susceptibility to carryover

yes (can be programmed to perform dilutions prior to analysis)/500 parts per million

Automatic rerun capability

yes

Sample volume can be diluted to rerun out-of-linear-range high results

yes

Sample volume can be concentrated to rerun out-of-linear-range low results

yes

Autocalibration/Multipoint calibration supported

yes (calibrants can be stored onboard)/yes (assay dependent)

Typical calibration frequency for ISE/therapeutic drugs/drugs of abuse/general chemistries/immunoassays

8 hrs./as needed/as needed/14 days/—

Automatic programmable start/Automatic programmable shutdown

yes/yes

Onboard real-time QC/Onboard software capability to review QC

yes/yes

Supports multiple QC lot numbers per analyte

yes

Waste management

automated collection onboard instrument or direct to drain

Sample barcode-reading capability/Autodiscrimination

yes (Interleaved 2 of 5, UPC, Codabar, Code 39, Code 128)/—

Lab can control analyzer from remote computer

no

Instrument can diagnose its own malfunctions

yes (operator intervention required to order parts)

System malfunctions can be diagnosed via remote monitoring

yes

UPS backup power supply

yes (optional)

Data-management capability/LIS or EHR systems interfaced

onboard/CGM Labdaq, Clinisys, Apollo, Paracelsus

LIS interface provided/Bidirectional interface capability

no/yes (host query)

Modem servicing provided/Service engineer on-site response time

no/1 business day

Mean time between failures

— (displays error codes for troubleshooting)

Average scheduled maintenance time by lab personnel

daily: < 5 min.; weekly: 1 hr.; monthly: 25 min.

Maintenance records kept onboard for user/vendor

yes (includes audit trail of who replaced parts)/some records (log)

Maintenance training demonstration module onboard

yes

Training included with purchase/Avg. time for basic user training

yes/3 days (online and at customer site)

Advanced operator training/Extra charge for follow-up or advanced training

no/—

Warranty provided/Cost of annual service contract (24 h/7 d)

yes (1 year)/—

Distinguishing features (supplied by company)

reagents: high-quality POINTE reagents, multiple lots calibrated/QC at once, reagents can be loaded while running; automated functions: startup, shutdown, calibration rerun, LIH, reflex, probe (liquid level, collision, clot, bubble, more); resource efficiency: low reagent and sample use

More products
in this guide

Alinity ci-series
ASI Evolution RPR Syphilis Analyzer
DxI 9000 Access Immunoassay Analyzer
Pictus 700 (P700)
Agility Automated ELISA System
Yumizen C1200
VITROS 3600 Immunodiagnostic System
VITROS 4600 Chemistry System
VITROS XT 7600 Integrated System
cobas pro integrated solutions
dIFine P30 Processor
IMMULITE 2000 XPi Immunoassay System
Phadia 250 Laboratory System
B⋅R⋅A⋅H⋅M⋅S KRYPTOR GOLD
QUANTA-Lyser 3000